Open AccessHyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women
Author(s) -
Delotte Jérôme,
Arias Tatiana,
Guerin Olivier,
Boulahssass Rabia,
Bereder Isabelle,
Bongain André,
Benchimol Daniel,
Bereder Jean Marc
Publication year - 2015
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1111/aogs.12577
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , ovarian cancer , cytoreductive surgery , chemotherapy , surgery , survival analysis , overall survival , cancer , oncology , stage (stratigraphy) , paleontology , biology
Our aim was to evaluate the morbidity and survival associated with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy ( HIPEC ) in the treatment of recurrent ovarian cancer for patients aged 70 years and older. We conducted a monocentric study in a French university hospital and collected data on 15 women aged ≥70 years, treated by cytoreduction and HIPEC for ovarian cancer relapse. The median overall survival was 35 months, with a median disease‐free survival of 15.6 months. When a Peritoneal Cancer Index subgroup analysis was performed, a statistically significant difference in the disease‐free survival could be observed for a Peritoneal Cancer Index ≤13 ( p = 0.036). A trend towards improvement of disease‐free survival was observed when the Completeness of Cytoreductive Score was equal to 0 ( p = 0.0915).